• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?

作者信息

Silvestris Nicola

机构信息

Medical Oncology Unit, IRCCS Istituto Tumori "Giovanni Paolo II" of Bari, 70124 Bari, Italy; Department of Biomedical Sciences and Human Oncology, University of Bari "Aldo Moro", 70124 Bari, Italy.

出版信息

EBioMedicine. 2021 Dec;74:103733. doi: 10.1016/j.ebiom.2021.103733. Epub 2021 Dec 1.

DOI:10.1016/j.ebiom.2021.103733
PMID:34864362
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8635463/
Abstract
摘要

相似文献

1
What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?免疫功能低下患者对BNT162b2 mRNA疫苗的免疫反应是什么？
EBioMedicine. 2021 Dec;74:103733. doi: 10.1016/j.ebiom.2021.103733. Epub 2021 Dec 1.
2
SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses.接受间隔16周剂量的BNT162b2 mRNA疫苗接种的个体血浆对SARS-CoV-2奥密克戎刺突蛋白的识别
Cell Rep. 2022 Mar 1;38(9):110429. doi: 10.1016/j.celrep.2022.110429. Epub 2022 Feb 8.
3
Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19.BNT162b2 mRNA 疫苗接种后细胞和体液功能反应在 COVID-19 初治和恢复期患者中具有纵向差异。
Cell Rep. 2022 Jan 11;38(2):110235. doi: 10.1016/j.celrep.2021.110235. Epub 2021 Dec 21.
4
Modulation of innate immune response to mRNA vaccination after SARS-CoV-2 infection or sequential vaccination in humans.SARS-CoV-2 感染后或序贯接种 mRNA 疫苗对人体固有免疫反应的调节。
JCI Insight. 2024 May 8;9(9):e175401. doi: 10.1172/jci.insight.175401.
5
The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't.接受检查点抑制剂治疗的癌症患者接种新冠病毒mRNA疫苗：我们已知与未知的情况
Immunotherapy. 2022 Feb;14(2):91-94. doi: 10.2217/imt-2021-0235. Epub 2021 Nov 8.
6
Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.癌症患者接种新冠病毒mRNA疫苗后的抗体和T细胞免疫反应。
Cancer Cell. 2021 Aug 9;39(8):1034-1036. doi: 10.1016/j.ccell.2021.07.016. Epub 2021 Jul 27.
7
Real-World Effectiveness and Immunogenicity of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Patients on Hemodialysis.血液透析患者中 BNT162b2 和 mRNA-1273 SARS-CoV-2 疫苗的真实世界有效性和免疫原性。
J Am Soc Nephrol. 2022 Jan;33(1):49-57. doi: 10.1681/ASN.2021060778. Epub 2021 Nov 17.
8
NK cell frequencies, function and correlates to vaccine outcome in BNT162b2 mRNA anti-SARS-CoV-2 vaccinated healthy and immunocompromised individuals.BNT162b2 mRNA 抗 SARS-CoV-2 疫苗接种健康和免疫功能低下个体的 NK 细胞频率、功能及其与疫苗结果的相关性。
Mol Med. 2022 Feb 8;28(1):20. doi: 10.1186/s10020-022-00443-2.
9
Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity.年龄相关的对 BNT162b2 疫苗诱导的针对 SARS-CoV-2 阿尔法和贝塔变异株的中和作用的降低。
Microbiol Spectr. 2021 Dec 22;9(3):e0056121. doi: 10.1128/Spectrum.00561-21. Epub 2021 Dec 1.
10
SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans.SARS-CoV-2 mRNA 疫苗可在人体内引发强烈且持久的滤泡辅助性 T 细胞反应。
Cell. 2022 Feb 17;185(4):603-613.e15. doi: 10.1016/j.cell.2021.12.026. Epub 2021 Dec 23.

引用本文的文献

1
Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine in adult patients with systemic sclerosis.系统性硬化症成年患者对 BNT162b2 新冠病毒 mRNA 疫苗的抗体反应。
Clin Rheumatol. 2022 Sep;41(9):2755-2763. doi: 10.1007/s10067-022-06219-7. Epub 2022 May 26.

本文引用的文献

1
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.在一项前瞻性、开放性标签临床试验中，评估了 mRNA BNT162b2 疫苗在五组免疫功能低下患者和健康对照者中的安全性和有效性。
EBioMedicine. 2021 Dec;74:103705. doi: 10.1016/j.ebiom.2021.103705. Epub 2021 Nov 30.
2
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.成年人实体瘤中接受两剂和三剂 BNT162b2 mRNA 疫苗的免疫反应。
Nat Med. 2021 Nov;27(11):2002-2011. doi: 10.1038/s41591-021-01542-z. Epub 2021 Sep 30.
3
Decline of antibody titres 3 months after two doses of BNT162b2 in non-immunocompromised adults.非免疫功能低下的成年人接种两剂 BNT162b2 后 3 个月抗体滴度下降。
Clin Microbiol Infect. 2022 Jan;28(1):139.e1-139.e4. doi: 10.1016/j.cmi.2021.08.023. Epub 2021 Sep 9.
4
COVID-19 Vaccination in Fragile Patients: Current Evidence and an Harmonized Transdisease Trial.脆弱患者的 COVID-19 疫苗接种：当前证据和跨疾病的协调试验。
Front Immunol. 2021 Aug 10;12:704110. doi: 10.3389/fimmu.2021.704110. eCollection 2021.
5
Poor humoral and T-cell response to two-dose SARS-CoV-2 messenger RNA vaccine BNT162b2 in cardiothoracic transplant recipients.心脏和胸部移植受者对两剂 SARS-CoV-2 信使 RNA 疫苗 BNT162b2 的体液和 T 细胞应答较差。
Clin Res Cardiol. 2021 Aug;110(8):1142-1149. doi: 10.1007/s00392-021-01880-5. Epub 2021 Jul 9.
6
BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response.BNT162b2 疫苗在心脏移植受者中的应用：临床经验和抗体反应。
J Heart Lung Transplant. 2021 Aug;40(8):759-762. doi: 10.1016/j.healun.2021.04.003. Epub 2021 Apr 21.
7
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
8
Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment.COVID-19 中的细胞因子风暴：发病机制和治疗中使用的抗炎药物概述。
Clin Rheumatol. 2020 Jul;39(7):2085-2094. doi: 10.1007/s10067-020-05190-5. Epub 2020 May 30.